# A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

> **NCT04846491** · PHASE3 · COMPLETED · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 475 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Peginterferon alfa-2b injection
- **DRUG:** Peginterferon alfa-2b injection
- **DRUG:** TDF
- **DRUG:** Peginterferon alfa-2b injection

## Key facts

- **NCT ID:** NCT04846491
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-04
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-12-07
- **Target enrollment:** 475 (ACTUAL)
- **Last updated:** 2024-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04846491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04846491, "A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04846491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*